Company Overview and News
U.S. equities have rebounded from a short-lived scare regarding a possible pullback of Chinese buying of U.S. Treasury bonds. The holiday-season melt has resumed, with stocks enjoying one of their strongest starts to a year on record. Just days after the Dow Jones Industrial Average passed the 25,000 threshold for the first time, the index is now closer to 26,000 than that level. (167-2)
Today we will discuss Lipocine (LPCN), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy (TRT). (243-7)
BOSTON, MA--(Marketwired - November 21, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has been appointed Chairman of the Board of Directors. Mr. Geraghty replaces Chau Q. Khuong, who is stepping down from the Board after helping guide Pieris through platform validation and partnerships to its transition into a fully-integrated research and clinical development company. (118-1)
Investors in Idera Pharmaceuticals, Inc. (IDRA - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $4 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (73-2)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has 80 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 54,821,190 shares. Largest shareholders include Baker Brothers Advisors LP, BlackRock Inc., Vanguard Group Inc, Broadfin Capital, LLC, and FMR LLC / Fidelity Management & Research. (104-2)
If you want a Stock Review on GALE, IDRA, RXDX, or JAGX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, the NASDAQ Composite ended the day at 6,448.47, up 0.30%; the Dow Jones Industrial Average edged 0.29% higher, to finish at 22,268.34; and the S&P 500 closed at 2,500.23, marginally gaining 0.18%. Gains were broad based as six out of nine sectors finished the trading session in green. (207-4)
From Ionis Pharmaceuticals' (NASDAQ:IONS) perspective, Glaxosmithkline's (NYSE:GSK) decision to opt out of its collaboration on inotersen and Ionis-FB-LRX is not the worst outcome that could befall it. After all, Glaxo had paid $35m seven years ago to secure rights for up to six Ionis antisense assets, and along the way kicked in more than $50m in collaboration revenue for a clinical program that required fewer than 200 patients to be filing ready in TTR amyloidosis. (0-1)
Last week portfolio returned 3.24% for the week compared to S&P 500 -0.62% for the week
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-1)
The U.S. stock market posted slight losses Thursday as the day’s focus turned to the Senate health bill, which will come to a vote next week. The S&P 500 Index and the Dow Jones Industrial Average lost 0.1% apiece, while the Nasdaq Composite gained a fraction of a percentage by day’s end.
BOSTON, MA--(Marketwired - May 22, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has joined the Company's Board of Directors, bringing the total number of directors to eight.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
IPO quiet period for TOCA expires on 5.8; on 5.9 underwriters Evercore, Leerink, and Stifel will likely release positive reports.
The biotech sector continues to drift aimlessly within a tight trading range and almost all movement across the sector is currently due to company specific news and events. (0-1)
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton